| Literature DB >> 35712024 |
Hao Tian1, Hanhan Shi1, Jie Yu1, Shengfang Ge1, Jing Ruan1.
Abstract
Oncological diseases have become the second leading cause of death from noncommunicable diseases worldwide and a major threat to human health. With the continuous progress in cancer research, the mechanical cues from the tumor microenvironment environment (TME) have been found to play an irreplaceable role in the progression of many cancers. As the main extracellular mechanical signal carrier, extracellular matrix (ECM) stiffness may influence cancer progression through biomechanical transduction to modify downstream gene expression, promote epithelial-mesenchymal transition (EMT), and regulate the stemness of cancer cells. EMT is an important mechanism that induces cancer cell metastasis and is closely influenced by ECM stiffness, either independently or in conjunction with other molecules. In this review, the unique role of ECM stiffness in EMT in different kinds of cancers is first summarized. By continually examining the significance of ECM stiffness in cancer progression, a biomimetic culture system based on 3D manufacturing and novel material technologies is developed to mimic ECM stiffness. The authors then look back on the novel development of the ECM stiffness biomimetic culture systems and finally provide new insights into ECM stiffness in cancer progression which can broaden the fields' horizons with a view toward developing new cancer diagnosis methods and therapies.Entities:
Keywords: biomimetic culture system; epithelial‐mesenchymal transition; epithelial‐mesenchymal transition stiffness; mechanotransduction; tumor microenvironment
Year: 2022 PMID: 35712024 PMCID: PMC9189138 DOI: 10.1002/gch2.202100094
Source DB: PubMed Journal: Glob Chall ISSN: 2056-6646
Elastic moduli of different tissues under physiological and pathological status
| Tissue | Physical stiffness | Pathological stiffness | Ref. |
|---|---|---|---|
| Lung | 150–200 Pa | 15 kPa (Fibrosis) |
[
|
| Brain | 50–450 Pa | 7–26.7 kPa (Glioblastoma) |
[
|
| Breast | 800 Pa | 5–10 kPa (Cancer) |
[
|
| Gastric | ≈0.5–1 kPa | ≈7 kPa (Cancer) |
[
|
| Pancreas | 1–2.9 kPa | 3.7 kPa (Cancer) |
[
|
| Liver | 2.1 kPa | >6 kPa (Cirrhosis) |
[
|
| Skin | 80–160 MPa | / |
[
|
| Bone | 2–5 GPa | / |
[
|
Figure 1With the tumor progression, the ECM stiffness is generally increasing, mainly due to the increased matrix deposition, the crosslinking of collagen, strain stiffening, elevated cell density, and increased interstitial fluid pressure. Besides, the crosstalking‐between cellular consortiums in tumors facilitated this process.
Figure 2The mechanical transduction pathway network plays a role in stiffness‐mediated EMT by regulating target genes. The TGFβ family activates downstream pathways through the TβR to promote EMT. Through mechanical transduction pathways, ECM stiffness activates different downstream molecules and then regulates the activation of EMT‐TF, which controls the downstream gene transcription such as upregulating mesenchymal markers, elevating cell membrane receptor expression, and downregulating epithelial markers. The dotted line indicates that there is a relationship in upregulation, but the direct action needs further confirmation.
Figure 3Inducers and intracellular pathways involved in stiffness‐mediated EMT in different types of cancers. The mechanotransduction pathways in different types of cancers are not the same. In most cases, a stiff ECM can promote EMT in cancer cells, while in H‐Ras‐transformed MCF10A cells and metastatic OCCs, it is a soft matrix that promotes EMT.
Figure 4Diagram of 2D and 3D culture system. Different strategies to construct 3D culture systems for studying physical cues (upper part). The concentric circles represent the strengths, shortages, and strategies of different cultural systems from the inside out. More details are available in Table 2.
Novel scaffold‐based culture systems used to study the role of ECM stiffness in cancers
| Culture system | Materials | Specialty | Cell type | Ref. | |
|---|---|---|---|---|---|
| PG scaffold | GG−Silk Spongy‐like Hydrogel | GG and Silk protein | Combining GG with silk protein can fabricate the hydrogel network allowing cell adhesion, and the stiffness can be controlled by modifying the mixing ratio of GG‐Silk. | Osteosarcoma |
[
|
| 3D porous chitosan‐CS (C‐CS) scaffolds | Chitosan and CS | Through adding CS to a chitosan scaffold, the biomaterial scaffolds appear to have an effect similar to PG versican, and C‐CS scaffolds are a suitable culture platform in vitro for PCa. | Prostate cancer |
[
| |
| 3D porous chitosan‐alginate (CA) scaffolds | Chitosan and Alginate | Chitosan is cationic and can interact with anionic polymers to form polyelectrolyte complexes (PECs). PECs can provide the advantages of each polymer in the complex, meanwhile hiding their respective weakness. | Prostate cancer glioma |
[
| |
| Binding bioactive ingredients | Bioactive peptides modified PEG scaffold |
PEG‐PQ PEG‐RGDS | The PEG hydrogels can be modified to render hydrogels bioactive and alter stiffness independently. | Lung cancer |
[
|
| 3D PEGDA/GelMA hydrogel matrix | PEGDA and GelMA | Gels incorporating GelMA have an RGD motif in the sequence and the ability to bind cells. Altering the ratio of PEGDA and GelMA permits manipulation of the matrix ligand density and stiffness, respectively, without changing other properties. | Osteosarcoma |
[
| |
| PEG‐fibrinogen (PF) hydrogel | PEGDA and Fibrinogen | The Young's modulus of PF hydrogels can be altered by increasing the amount of PEGDA. | Breast cancer |
[
| |
| PEG‐heparin‐based 3D model | PEG and Heparin | By coupling cysteine residues within the four‐arm PEG and maleimide‐modified heparin, the mechanical properties can be altered independently without affecting ligand density. | Breast cancer |
[
| |
| PEG‐SH scaffold hydrogel | PEG‐disthiol | Linear PEG‐disthiol (PEG‐SH) and MMP‐cleaved sequence (CGPQGIWGQC) are crosslinked and the cell adhesion peptides (CRGDS) can promote cell adhesion. | Brain tumor |
[
| |
| Alginate–RGD hydrogels | Alginate | Through coupling the oligopeptide GGGGRGDSP to the alginate to allow cell adhesion. | Osteosarcoma |
[
| |
| Modified HA hydrogel | HA | The acrylate HA is crosslinked with an enzymatically degradable peptide and two cysteines, and incorporates adhesion through RGD, forming a modular culture system. | Fibrosarcoma |
[
| |
| HA | By using two biorthogonal chemical strategies (oxime ligation and Diels–Alder reaction) within the same HA polymer backbone, the stiffness and bioactivity of the hydrogel can be independently modulated. | Breast cancer |
[
| ||
| Collaborating with other materials | 3D bioprinted dECM scaffolds | dECM and GelMA | Liver dECM is combined with GelMA to produce a photocrosslinkable solution, which is printed into hexagonal lobules close to the size of liver lobules using a rapid 3D bioprinting technology based on DLP. Changes in stiffness can easily be controlled by changing the exposure time. | Liver cancer |
[
|
| 3D salmon fibrin gel | Thrombin‐activated purified fibrinogen | This mechanistic approach is useful for screening stem‐cell‐like cancer cells independently of stem cell markers. |
Melanoma Ovarian cancer Liver cancer Lymphoma |
[
| |
| 3D matrices with type I collagen Oligomer (IM) | Col I oligomer and Matrigel | Oligomer can polymerize rapidly to form highly interconnected D‐banded collagen‐fibril networks, which are similar to the networks found in tissues in vivo. | Pancreatic cancer |
[
| |
| IPN 3D coculture hydrogel system | Alginate and Matrigel | Allowing alteration of ECM stiffness independently of composition and 3D architecture, the average pore size is similar for all the IPNs, therefore, not affecting diffusion. |
Lung cancer Breast cancer |
[
| |
| Collagen‐IV‐coated PA gel | PA and Collagen‐IV | Functionalized a layer of col‐IV to mimic BM‐like properties. | Breast cancer |
[
| |
| Dynamic stiffness | Thermal induced crosslinking | Alginate | Temperature‐sensitive liposomes using encapsulated gold nanorods will release calcium or chelator when exposed to NIR light, resulting in alginate gelation and crosslinking. | / |
[
|
| Photopolymerization | MeHA | Using dithiothreitol as a cross‐linking agent, the MeHA hydrogel network is further cross‐linked by UV light after cell inoculation to the hydrogel. | Breast cancer |
[
| |
| Enzymatic crosslinking | Thiol‐norbornene and 4‐hydroxyphenylacetic acid‐modified gelatin | In norbornene and 4‐hydroxyphenylacetic acid‐modified gelatin, di‐tyrosine crosslink is then catalyzed by tyrosinase, realizing the on‐demand stiffening. | Pancreatic cancer |
[
|
[Abbreviation] CS: Chondroitin sulfate; dECM: decellularized extracellular matrix; GelMA: Methacrylated gelatin; GG: Gellan gum; MeHA: Methacrylated glycosaminoglycan hyaluronic acid; PA: polyacrylamide; PEG: polyethylene glycol; PEGDA: Poly (ethylene glycol) diacrylate.
Figure 5Stiffness‐mediated EMT occurs in cancer cells. ECM stiffness can independently act as a force cue or synergistically stimulate EMT in cancer cells with costimulators, including biochemical (such as TGFβ family, LOX family, MMP3) and physical factors (ECM topography, adhesion ligands concentration, hypoxia, etc.). In soft matrix cases, the loss of E‐cadherin in cancer cells impairs the balance between cell–cell adhesions and integrins‐mediated cell‐ECM adhesion, resulting in the occurrence of metastasis and invasion. The thin dotted line means that the effect is minor.
Figure 6Perspectives for future ECM stiffness studies. Much work needs to be done, including identifying specific mechanisms in diverse cancers, deeply exploring the mechanism of ECM stiffness in tumor progression, and developing culture systems more akin to living tissues.